TALK vs. WGS, VCYT, ARDT, ADUS, PGNY, NHC, PACS, GRAL, AHCO, and TDOC
Should you be buying Talkspace stock or one of its competitors? The main competitors of Talkspace include GeneDx (WGS), Veracyte (VCYT), Ardent Health Partners (ARDT), Addus HomeCare (ADUS), Progyny (PGNY), National HealthCare (NHC), PACS Group (PACS), Grail (GRAL), AdaptHealth (AHCO), and Teladoc Health (TDOC). These companies are all part of the "healthcare" industry.
Talkspace vs. Its Competitors
Talkspace (NASDAQ:TALK) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Talkspace has a net margin of 0.61% compared to GeneDx's net margin of -17.12%. GeneDx's return on equity of 3.33% beat Talkspace's return on equity.
Talkspace currently has a consensus price target of $4.50, indicating a potential upside of 45.16%. GeneDx has a consensus price target of $86.75, indicating a potential upside of 23.36%. Given Talkspace's stronger consensus rating and higher possible upside, equities analysts plainly believe Talkspace is more favorable than GeneDx.
Talkspace has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
57.4% of Talkspace shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 23.5% of Talkspace shares are held by company insiders. Comparatively, 29.6% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
GeneDx received 8 more outperform votes than Talkspace when rated by MarketBeat users. Likewise, 51.85% of users gave GeneDx an outperform vote while only 40.00% of users gave Talkspace an outperform vote.
In the previous week, Talkspace had 6 more articles in the media than GeneDx. MarketBeat recorded 9 mentions for Talkspace and 3 mentions for GeneDx. GeneDx's average media sentiment score of 1.25 beat Talkspace's score of 0.84 indicating that GeneDx is being referred to more favorably in the news media.
Talkspace has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Talkspace, indicating that it is currently the more affordable of the two stocks.
Summary
GeneDx beats Talkspace on 11 of the 19 factors compared between the two stocks.
Get Talkspace News Delivered to You Automatically
Sign up to receive the latest news and ratings for TALK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TALK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talkspace Competitors List
Related Companies and Tools
This page (NASDAQ:TALK) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy TALK Stock Free TALK Stock Alerts